Tranquillizing drugs fall into two main categories. The first group consists of such drugs as meprobamate and suavitil, which are being used in the treatment of the neuroses and milder anxiety states. The second group consists of drugs which are, in the main, phenothiazine derivatives, such as chlorpromazine, pacatal, sparine, etc. and these drugs have been found to have a place in the treatment of the psychotic patient.
This review is concerned with the second group of drugs and with pacatal in particular. Pacatal is io (I-methyl-3-piperidylmethyl) phenothiazine. It was synthesized in I953 and tested pharmacologically by Niescholz et al. (I954) . In many ways it resembles chlorpromazine in its action, but it is not so powerful a sedative and its side effects are different. This will be discussed subsequently.
The chief clinical problem facing psychiatrists today is the treatment of the chronic population of the mental hospital. This group consists of patients who have missed the opportunity of having E.C.T., insulin coma therapy or pre-frontal leucotomy early in their illnesses, or else they have failed to respond to such measures. These patients have been subjected to In view of the bewildering variety of tranquillizing drugs now available, it is obviously the task of the clinical investigator to assess each one in an attempt to find out which variety of mental illness will respond best to a particular drug. It seems unlikely that a drug will appear which will be a panacea for all psychoses.
In the present state of knowledge, it would appear that chlorpromazine and reserpine (a rauwolfia derivative) have an established place in the treatment of the chronic schizophrenic patient (Leiberman and Vaughan, 1957 they considered that the incidence of side effects was higher than those due to chlorpromazine. Simpson (1957) found it useful in the treatment of the chronic psychotic and noted it to be particularly effective where aggression, impulsiveness and overactivity were prominent. Gillie (xI957) found the drug to be of limited value in the control of behaviour in a group of mental defective patients, but she considered that of I4 epileptics seven showed some improvement of note. Pacatal has been in general use at Cane Hill since May 1956. Since our findings were quite different from those of the above writers it was thought that they were worthy of description.
The first half of this investigation consisted of giving the drug to a fairly large number of chronic deteriorated female in-patients. This group had been given chlorpromazine previously and had shown some evidence of improvement, but no sign of complete recovery. The second half was taken up with evaluating the drug in the treatment of a variety of psychiatric disorders in the hope of defining accurate clinical indicatiQns.
Method
The design of the experiment has been as follows. In view of the fact that there was no ward in the hospital where tranquillizers had not been used, no fresh population was available to us for the trial of pacatal. Therefore the plan was made of taking two identicaI wards where chlorpromazine was already in use. In one ward pacatal was to be substituted for chlorpromazine and the behaviour of the patients in that ward was to be contrasted with the behaviour of the patients in the other ward where chlorpromazine was in use. The plan of the experiment was kept secret from the nursing staff who were told simply that this was a drug, similar to chlorpromazine, which was not expected to be any better than chlorpromazine. In all 50 patients were changed from cliorpromazirne to pacatal in doses varying from I50 to 300 mg. daily. Most of the patients are chronic schizophrenics. They showed a clinical picture which varied from stupor to aggressive excitement. They complained that they were persecuted and they also experienced auditory hallucinations. Their habits were filthy and they behaved in a destructive way. Food had little interest for them and they appeared to be quite lost and cut off from normal human intercourse. The average age of these patients is 50 years and their length of stay in hospital varied from two to 40 years. ,
Results
The changeover from chlorpromazine to pacatal was effected without incident about two years ago.
A recent survey of these $o patients showed the following results: 42 (84 per cent.) showed evidence of improvement and only 8 (I6 per cent.)
showed no change. It should be emphasized that the phrase ' no change' meant that they were as well sedated by pacatal as they had been previously by chlorpromazine. The form the improvement took was that the patient became more animated. The ward staff noted that the patients were much more responsive and communicative. They would dress and wash themselves and would come to the meal table when called to do so. This spontaneity of speech and action was really quite strilding. One patient who had been mute and uncommunicative for many years rediscovered her powers of speech and was able to tell the ward doctor that she was suffering from depression. She was then given a course of E.C.T. with further improvement. Another patient described how her mind felt much clearer and she was able to plan and think much more easily. The most striking change in these patients was the degree of emotional improvement. They showed cheerfulness, emotional warmth and responsiveness to a much greater extent than that encountered commonly in schizophrenics.
Further Findings
In view of the fact that this group of patients tolerated pacatal well and showed some signs of improvement, it was decided to extend its These consisted commonly of dry mouth, dilation of pupils and leucopenia. Dry mouth occurred in about 5 per cent. of this series. Dilation of pupils occurred in io per cent., but this group was chiefly under the age of 50 and an even smaller proportion complained of inability to read. Leucopenia was seen in 4 per cent. of the patients, all of whom had routine white cell counts.
The lowest cell count noted was 3,000 W.B.C. This improved when the drug was omitted. In one patient the white cell count was found to be 4,0ooo00 c.mm. Pacatal The chronic schizophrenics were helped to some extent, but none was discharged from hospital.
The improvement noted in all patients consisted of an increased clarity of thought, fading of delusions and hallucinations, and improvement in social behaviour.
Side effects were few and consisted of dry mouth (5 per cent.) pupillary changes (io per cent.) and leucopenia (4 per cent.). No fatal case of agranulocytosis developed, and in one patient the white cell count returned to normal levels in spite of the fact that the drug was not discontinued.
Dosage levels varied from 75 to 300 mg. daily but on the whole the commonest dose was 150 mg.
daily.
In the main the patients helped most were in the older age groups. It is among these patients that pacatal appears to be more useful than any of the tranquillizing drugs in current use. However, it is important to select one's patients carefully, and to review their progress frequently.
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